IL-WEBER
Weber Inc . (“Weber” or “the Company”) today announced it has established 1952 Ventures LLC , a new subsidiary that will serve as an accelerator of new growth platforms and brand extensions for Weber in the areas of product, technologies, and partnerships. Troy Shay, Chief Commercial Officer of Weber Inc., has been appointed Chief Executive Officer of 1952 Ventures LLC and Chief Growth Officer of Weber. The Company also announced five additional senior leadership appointments and promotions in its Global Operations and Americas and European Operating Segments.
Troy Shay, Chief Executive Officer, 1952 Ventures LLC and Chief Growth Officer of Weber Inc.
Since joining Weber in 2018, Mr. Shay has led the Company’s Americas business in the U.S., Canada, and Latin America. He has been instrumental in managing several strategic Weber commercial initiatives, resulting in exceptional company growth. In his new position, effective December 1, 2021, Mr. Shay will focus on future business development initiatives for Weber and is responsible for identifying and developing new platforms that expand the Company’s product and brand portfolios globally.
Beau Warren Promoted to President Weber Americas
Effective December 1, 2021, Beau Warren will serve as President Weber Americas, succeeding Mr. Shay. Mr. Warren, who joined Weber in 2019 from Fortune Brands, currently serves as Senior Vice President and General Manager of Weber’s U.S. business, which has shown substantial revenue expansion under his leadership.
Michael Jacobs Appointed Chief Operating Officer of Weber Inc.
Michael Jacobs, Chief Supply Chain Officer, has been appointed to the role of Chief Operating Officer. Mr. Jacobs joined Weber in 2014 and most recently served as Chief Supply Chain Officer, leading the Company’s multi-continent manufacturing footprint and global supply chain. In his new position, Mr. Jacobs will oversee end-to-end operations for Weber, from its innovation engine to manufacturing and its customer-facing supply chain.
Jennifer Bonuso Promoted to Senior Vice President and General Manager, Global Product of Weber Inc.
Jennifer Bonuso will serve as Senior Vice President and General Manager, Global Product. Since joining Weber in 2019 from Honeywell and Whirlpool, Mrs. Bonuso has led the creation and management of an industry-leading new product pipeline.
Hans-Jurgen Herr Appointed President Emeritus and EVP Growth Projects, Weber EMEA
Effective December 1, 2021, Hans-Jürgen Herr, currently President of Weber EMEA, will transition to President Emeritus and EVP Growth Projects as part of a planned multi-year succession process. An 18-year veteran of Weber, Mr. Herr has served as President of Weber EMEA for nine years. Through his tenure as President, he has nearly tripled Weber’s business across the region. In his new role, Mr. Herr will lead several growth projects for the Company and serve in an advisory capacity for Weber’s large and growing EMEA business.
Steffen Hahn, Ph.D., Appointed In-Coming President of Weber EMEA
Dr. Steffen Hahn, currently Senior Vice President Commercial of Weber EMEA, will succeed Mr. Herr as President of Weber EMEA, effective December 1, 2021. Dr. Hahn joined Weber in early 2020 as part of a planned succession strategy. Since joining the Company, he has significantly contributed to accelerating Weber’s growth in EMEA. Before Weber, Dr. Hahn worked across a range of successful consumer business engagements at McKinsey & Company and Procter & Gamble.
“The start of 1952 Ventures along with the appointments and promotions of several senior leaders position us for continued growth and market leadership,” said Chris Scherzinger, Chief Executive Officer of Weber. “I believe a company’s success reflects the talents of its team, and we have the best global team in the business. We’ll leverage the market-leading strength of our people, our iconic brand, and our worldwide reach to drive new growth platforms and innovative ventures with world-class execution.”
“I want to thank Troy, Beau, Mike, Jennifer, Hans, and Steffen for their leadership and commitment to our Weber team members around the world and our loyal consumers and fans. I am delighted each of them will continue to work closely with me to execute our strategic plan and take our cherished brand to new heights,” added Mr. Scherzinger.
Weber Inc., headquartered in Palatine, Ill., is the world’s leading barbecue brand. The Company’s founder George Stephen, Sr., established the outdoor cooking category when he invented the original charcoal grill nearly 70 years ago. Weber offers a comprehensive, innovative product portfolio, including charcoal, gas, pellet and electric grills, smokers, and accessories designed to help outdoor cooking enthusiasts discover what’s possible. Earlier this year, the Company acquired June Life Inc., a smart appliance and technology company, to accelerate the development of its Weber Connect® technology and digital products. Weber offers its barbecue grills and accessories, services, and experiences to a passionate community of millions across 78 countries.
Weber Connect® is a registered trademark of Weber-Stephen Products LLC.
FORWARD-LOOKING STATEMENTS
This press release contains various “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, which represent Weber’s expectations or beliefs concerning future events. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” the negative of these terms and other comparable terminology. These forward-looking statements, which are subject to risks, uncertainties and assumptions about us, may include projections of our future financial performance, our anticipated growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements, including those factors discussed in the section titled “Risk Factors” in our Registration Statement (Registration No. 333-257824) on Form S-1. Our future results could be affected by a variety of other factors, including uncertainty of the magnitude, duration, geographic reach, impact on the global economy and current and potential travel restrictions of the COVID-19 outbreak, the current, and uncertain future, impact of the COVID-19 outbreak on our business, growth, reputation, prospects, financial condition, operating results (including components of our financial results), and cash flows and liquidity, risks relating to any unforeseen changes to or effects on liabilities, future capital expenditures, revenues, expenses, earnings, synergies, indebtedness, financial condition, losses and future prospects, the ability to realize the anticipated benefits and synergies from business acquisitions in the amounts and at the times expected, the impact of competitive conditions, the effectiveness of pricing, advertising, and promotional programs; the success of innovation, renovation and new product introductions; the recoverability of the carrying value of goodwill and other intangibles, the success of productivity improvements and business transitions, commodity and energy prices, transportation costs, labor costs, disruptions or inefficiencies in supply chain, the availability of and interest rates on short-term and long-term financing, the levels of spending on systems initiatives, properties, business opportunities, integration of acquired businesses, and other general and administrative costs, changes in consumer behavior and preferences, the effect of U.S. and foreign economic conditions on items such as interest rates, statutory tax rates, currency conversion and availability, legal and regulatory factors including the impact of any product recalls; and business disruption or other losses from war, pandemic, terrorist acts or political unrest.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211118005847/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
